Edition:
United Kingdom

Novus Therapeutics Inc (NVUS.OQ)

NVUS.OQ on NASDAQ Stock Exchange Capital Market

4.11USD
15 Dec 2017
Change (% chg)

$-0.04 (-0.96%)
Prev Close
$4.15
Open
$4.24
Day's High
$4.24
Day's Low
$4.11
Volume
1,008
Avg. Vol
3,293
52-wk High
$15.12
52-wk Low
$3.42

Chart for

About

Novus Therapeutics, Inc., formerly Tokai Pharmaceuticals, Inc., is a pharmaceutical company. The Company is focused on the acquisition, development, and commercialization of ear, nose, and throat products. It has two platforms: OP-01 Foam Platform and OP-02 Surfactant Program. OP-01 is developed with the intent to be used as a... (more)
No analyst recommendations are available for .

Overall

Beta: --
Market Cap(Mil.): $33.47
Shares Outstanding(Mil.): 6.94
Dividend: --
Yield (%): --

Financials

  Industry Sector
P/E (TTM): -- 31.14 16.44
EPS (TTM): -- -- --
ROI: -- 14.86 10.62
ROE: -- 16.28 14.20

BRIEF-Novus Therapeutics Inc reported Q3 $0.43 loss per share​

* Novus Therapeutics Inc - ‍for Q3 of 2017, Novus reported $0.43 loss per share​ Source text: (http://bit.ly/2hldAkp) Further company coverage:

08 Nov 2017

BRIEF-Novus Therapeutics reports third quarter 2017 results

* Q3 loss per share $0.43 Source text for Eikon: Further company coverage:

08 Nov 2017

BRIEF-Novus Therapeutics reports Q2 loss per share $1.32

* Q2 loss per share $1.32 Source text for Eikon: Further company coverage:

10 Aug 2017

BRIEF-S.Africa's Competition Tribunal says Caxton cannot intervene in Media24-Novus merger

* Has rejected Caxton's application for leave to intervene in merger hearings concerning merger between Media24 and Novus

22 Jun 2017

Earnings vs. Estimates